Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of a novel endometrial cancer biomarker panel with prognostic risk, platinum insensitivity, and targetable therapeutic options.

PloS one - 1 Jan 2021

Bosquet Jesus Gonzalez, Zhang Qing, Cliby William A, Bakkum-Gamez Jamie N, Cen Ling, Dowdy Sean C, Sherman Mark E, Weroha S John, Clayton Amy C, Kipp Benjamin R, Halling Kevin C, Couch Fergus J, Podratz Karl C

Abstract excerpt

During the past decade, the age-adjusted mortality rate for endometrial cancer (EC) increased 1.9% annually with TP53 mutant (TP53-mu) EC disproportionally represented in advanced disease and deaths. Therefore, we aimed to assess pivotal molecular parameters that differentiate clinical outcomes in high- and low-risk EC. Using the Cancer Genome Atlas, we analyzed EC specimens with available DNA sequences and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endometrial Neoplasms

Share to Gene Expression Profiling

Share to Gene Expression Regulation, Neoplastic

Share to Neoplasm Invasiveness

Share to Neoplasm Proteins

Share to Organoplatinum Compounds

Source

Open in PubMed Open full text

Identifiers

PMID: 33503056
DOI: 10.1371/journal.pone.0245664
PMCID: PMC7840025

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of a novel endometrial cancer biomarker panel with prognostic risk, platinum insensitivity, and targetable therapeutic options.PMID 33503056Read ↗

Identification of TP53 mutated group using a molecular and immunohistochemical classification of endometrial carcinoma to improve prognostic evaluation for adjuvant treatments.Semantic proximity Read ↗

New therapeutic targets for endometrial cancer: a glimpse into the preclinical sphere.Semantic proximity Read ↗

Molecular testing for endometrial cancer: An SGO clinical practice statement.Semantic proximity Read ↗

Molecular subtypes of endometrial cancer: Implications for adjuvant treatment strategies.Semantic proximity Read ↗

The TCGA Molecular Classification of Endometrial Cancer and Its Possible Impact on Adjuvant Treatment DecisionsSemantic proximity Read ↗

The emerging role of molecular pathology in directing the systemic treatment of endometrial cancerSemantic proximity Read ↗

p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial.Semantic proximity Read ↗

Validation of comprehensive genomic profiling for prognostic and potential therapeutic molecular classification of endometrial cancer.Semantic proximity Read ↗

The mutational landscape of endometrial cancer.Semantic proximity Read ↗

Molecular Characterization and Clinical Implications of Endometrial Cancer.Semantic proximity Read ↗

Tailoring Endometrial Cancer Treatment Based on Molecular Pathology: Current Status and Possible Impacts on Systemic and Local Treatment.Semantic proximity Read ↗

Clinicopathologic and Genomic Analysis of TP53-Mutated Endometrial Carcinomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.